Alkermes plc. ALKS
The following discussion contains forward-looking statements. 10-K, Item 1
- Headquarters
- Dublin 4, L2
- CEO
- Richard F. Pops
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $1.5B through the costs to a net profit of $241.7M · income statement of the 10-K
ALKS among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
23 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 12, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Inventory growing faster than revenueInventory +7.5% ($182.9M to $196.6M) vs revenue -5.2% ($1.6B to $1.5B), +12.8 pts apart
-
Receivables -13.1% ($384.5M to $334.0M) vs revenue -5.2% ($1.6B to $1.5B), -7.9 pts apart
9 more checks with nothing to note
-
Cash from operations $520.8M vs net income $241.7M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Rebate Accruals - Medicaid Drug Rebate Program
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
23 paragraphs in Risk Factors that were not in the 10-K filed Feb 12, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
Additionally, the OBBBA, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program and the enhanced PPACA subsidies expired as of December 31, 2025. Such reductions and loss of subsidies are expected to decrease the number of individuals enrolled in Medicaid over time and reduce the services…
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
We may fail to realize some or all of the anticipated benefits and synergies of the Avadel Acquisition or to successfully integrate Avadel’s business, which could adversely affect our business and financial condition and the price of our ordinary shares. We completed the Avadel Acquisition successfully in February 2026. We are in the…
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
LUMRYZ is a controlled substance subject to U.S. federal and state-controlled substance laws and regulations, and any failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, could materially adversely affect our business, financial condition, cash flows and results of operations.…
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
In April 2025, Mural announced its intent to discontinue all clinical development of nemvaleukin alfa following a review of clinical trial data, reduce its workforce by approximately 90% and commence the exploration of strategic alternatives focused on maximizing shareholder value. In August 2025, Mural and XOMA Royalty Corporation…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.1B | $1.7B | $1.6B | $1.5B |
| Net income | −$158.3M | $355.8M | $367.1M | $241.7M |
| Operating cash flow | $21.0M | $401.4M | $439.1M | $520.8M |
| Free cash flow | −$17.2M | $353.3M | $405.6M | $480.3M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.5B ▼ 5.2% in FY2025$241.7M ▼ 34.2% in FY2025$480.3M ▲ 18.4% in FY2025
Recent filings
7 filings in the last 30 days · SEC EDGAR
-
8-KNov 12, 2026Material agreement signed 8-K item 1.01
-
Planned saleNov 3, 2026Gaffin David Joseph (Officer) gave notice of a planned sale of 2,035 shares worth about $94K Form 144, approximate sale date Nov 3, 2026, under a 10b5-1 plan adopted Nov 19, 2025
-
Planned saleNov 3, 2026Dr. Cato Laurencin (director) adopted a 10b5-1 trading plan reported in the 10-Q, up to 16,142 shares, runs to Dec 31, 2027
-
Planned saleNov 3, 2026Dr. Christopher Wright (director) adopted a 10b5-1 trading plan reported in the 10-Q, up to 39,297 shares, runs to Nov 18, 2027
-
Planned saleNov 3, 2026Shane Cooke (director) adopted a 10b5-1 trading plan reported in the 10-Q, up to 41,675 shares, runs to Aug 31, 2027
About the company
Alkermes plc., Dublin 4, L2 · from the 10-K filed Feb 25, 2026
The following discussion contains forward-looking statements. Actual results may differ significantly from those expressed or implied in the forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements” on page 3 of this Annual Report. Factors that might cause future results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to, those discussed in “Item 1A - Risk Factors” and elsewhere in this Annual Report.
- Headquarters
- Dublin 4, L2
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 12, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALKS/export.csv") into a cell.